SINCO PHARMA released its interim results, with a profit attributable to shareholders of HKD 24.389 million, an increase of 2.17% year-on-year
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, SINCO PHARMA released its performance for the six months ending June 30, 2025. During this period, the group achieved revenue of RMB 1.196 billion, a year-on-year decrease of 21.68%; the profit attributable to the company's owners was RMB 24.389 million, a year-on-year increase of 2.17%; the basic earnings per share were RMB 0.012
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments